ArticleBMC infectious diseases2025
COVID-19 pandemic disruptions drive decreases in HPV prevalence and shift genotype distribution in Western China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prevalence and genotype distribution of human papillomavirus in Sulaymaniyah, Kurdistan Region, Iraq.Frontiers in cellular and infection microbiology · 2026Article
- The Impact of COVID-19 Vaccination on HR-HPV Persistence and Cervical Cytology Outcomes: A Retrospective Study.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis population-based study investigated longitudinal changes in the prevalence and genotype distribution of HPV across the pre-pandemic (2017-2019), pandemic (2020-2022), and post-pandemic (2023-2024) periods in Western China.
methodsWe conducted a retrospective cohort analysis of 129,585 women, stratified into three chronological cohorts: pre-pandemic (n=40,044), pandemic (n=43,717), and post-pandemic (n=45,824) cohorts. Cervicovaginal specimens were analyzed via real-time PCR-based genotyping to detect 16 high-risk and 7 low-risk genotypes. Age-specific prevalence patterns were evaluated across six demographic strata (<20 to ≥60 years). Age-standardized prevalence rates were calculated using 2020 Chinese census data as a reference population.
resultsThe total HPV prevalence decreased from 31.59% before the pandemic to 23.28% during the pandemic, stabilizing at 21.45% after the pandemic. Nonvaccine-targeted HR-HPV subtypes (HPV-52, HPV-58) maintained persistent dominance across all phases, with the prevalence of HPV-52 decreasing from 6.00% before the pandemic to 3.00% after the pandemic. Adolescents (<20 years) presented the lowest infection rates, whereas peak rates were reported for women aged 40-49 years.
conclusionsThe sustained reduction in total HPV prevalence is potentially associated with pandemic-related behavioral modifications and healthcare disruptions. The persistent circulation of nonvaccine-targeted subtypes highlights gaps in current prevention strategies. These findings emphasize the need for comprehensive surveillance integrating catch-up screening and genotype-specific vaccine development to address post-pandemic HPV transmission dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.